February 1st, 2024Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma Vivek Subbiah1, Sant P. Chawla2, Anthony P. Conley3, Breelyn A. Wilky4, Anthony...
Read Article